Skip to search formSkip to main contentSkip to account menu

treprostinil diolamine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Treprostinil diolamine is the first oral dosage preparation of a prostacyclin analogue for use in treatment naive pulmonary… 
Review
2016
Review
2016
Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil… 
2014
2014
Pulmonary arterial hypertension (PAH) is a rare yet progressive and life-threatening condition that, despite the availability of… 
2014
2014
Pulmonary arterial hypertension (PAH) is a rare yet progressive and life-threatening condition that, despite the availability of… 
Highly Cited
2013
Highly Cited
2013
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled… 
2013
2013
Abstract: Pulmonary arterial hypertension (PAH) is a progressive vascular disease that ultimately leads to right ventricular… 
2013
2013
Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue under evaluation for the treatment for pulmonary arterial… 
2013
2013
Abstract: Treprostinil diolamine sustained release (UT-15C SR) is being evaluated as an oral therapy for pulmonary arterial… 
2013
2013
Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue currently being evaluated for the treatment of pulmonary… 
2013
2013
Abstract: Treprostinil, a stable prostacyclin analogue used in the treatment of pulmonary arterial hypertension, is in…